356 related articles for article (PubMed ID: 18090280)
1. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Murray JM; Emery S; Kelleher AD; Law M; Chen J; Hazuda DJ; Nguyen BY; Teppler H; Cooper DA
AIDS; 2007 Nov; 21(17):2315-21. PubMed ID: 18090280
[TBL] [Abstract][Full Text] [Related]
2. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Markowitz M; Nguyen BY; Gotuzzo E; Mendo F; Ratanasuwan W; Kovacs C; Prada G; Morales-Ramirez JO; Crumpacker CS; Isaacs RD; Gilde LR; Wan H; Miller MD; Wenning LA; Teppler H;
J Acquir Immune Defic Syndr; 2007 Oct; 46(2):125-33. PubMed ID: 17721395
[TBL] [Abstract][Full Text] [Related]
3. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
[TBL] [Abstract][Full Text] [Related]
4. Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT; Cooper DA; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Nguyen BY; Teppler H;
N Engl J Med; 2008 Jul; 359(4):339-54. PubMed ID: 18650512
[TBL] [Abstract][Full Text] [Related]
5. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lennox JL; DeJesus E; Lazzarin A; Pollard RB; Madruga JV; Berger DS; Zhao J; Xu X; Williams-Diaz A; Rodgers AJ; Barnard RJ; Miller MD; DiNubile MJ; Nguyen BY; Leavitt R; Sklar P;
Lancet; 2009 Sep; 374(9692):796-806. PubMed ID: 19647866
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir as effective as efavirenz in 144-week data.
AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
[No Abstract] [Full Text] [Related]
8. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
Delaugerre C
Med Mal Infect; 2010 Sep; 40 Suppl 1():S1-10. PubMed ID: 20800182
[TBL] [Abstract][Full Text] [Related]
9. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
[TBL] [Abstract][Full Text] [Related]
10. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
[TBL] [Abstract][Full Text] [Related]
11. [Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].
Llibre JM; Martínez-Picado J
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():17-22. PubMed ID: 19572421
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
[TBL] [Abstract][Full Text] [Related]
13. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
Stephan C; Baldauf HM; Barry J; Giordano FA; Bartholomae CC; Haberl A; Bickel M; Schmidt M; Laufs S; Kaderali L; Keppler OT
J Antimicrob Chemother; 2014 Oct; 69(10):2809-18. PubMed ID: 24962031
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Markowitz M; Morales-Ramirez JO; Nguyen BY; Kovacs CM; Steigbigel RT; Cooper DA; Liporace R; Schwartz R; Isaacs R; Gilde LR; Wenning L; Zhao J; Teppler H
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):509-15. PubMed ID: 17133211
[TBL] [Abstract][Full Text] [Related]
16. Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
[TBL] [Abstract][Full Text] [Related]
17. Role of raltegravir in HIV-1 management.
Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of an HIV Model with Multiple Infection Stages and Treatment with Different Drug Classes.
Wang X; Song X; Tang S; Rong L
Bull Math Biol; 2016 Feb; 78(2):322-49. PubMed ID: 26842389
[TBL] [Abstract][Full Text] [Related]
19. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
